Shopping Cart
- Remove All
Your shopping cart is currently empty
cFMS Receptor Inhibitor II
cFMS Receptor Inhibitor II is a CSF1R kinase (FMS Receptor; colony stimulating factor 1 receptor; Macrophage colony-stimulating factor receptor) inhibitor with an IC50 of 2.8 nM, demonstrating significant selectivity over other kinases. This compound also exhibits notable CSF1R inhibition with an IC50 of 1.4 μM in cellular assays.
Catalog No. T5586Cas No. 959860-85-6
Select Batch
Purity:99.80%
Contact us for more batch information
cFMS Receptor Inhibitor II
Catalog No. T5586Cas No. 959860-85-6
cFMS Receptor Inhibitor II is a CSF1R kinase (FMS Receptor; colony stimulating factor 1 receptor; Macrophage colony-stimulating factor receptor) inhibitor with an IC50 of 2.8 nM, demonstrating significant selectivity over other kinases. This compound also exhibits notable CSF1R inhibition with an IC50 of 1.4 μM in cellular assays.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $42 | In Stock | |
| 2 mg | $59 | In Stock | |
| 5 mg | $98 | In Stock | |
| 10 mg | $156 | In Stock | |
| 25 mg | $268 | In Stock | |
| 50 mg | $396 | In Stock | |
| 100 mg | $575 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $108 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "cFMS Receptor Inhibitor II"
Pexidartinib
Cited
PLX-3397
T21151029044-16-3
Pexidartinib (PLX-3397) is a capsule containing a small-molecule receptor tyrosine kinase (RTK) inhibitor targeting KIT, CSF1R, and FLT3, with potential antineoplastic activity.
- $40
Size
QTY
CitedPLX5622 Cited
PLX-5622
T71001303420-67-8
PLX5622 is a highly selective, brain-penetrant, and orally active CSF1R inhibitor.
- $97
Size
QTY
CitedSotuletinib Cited
BLZ945
T6119953769-46-5
Sotuletinib (BLZ945) is an orally active, effective and specific CSF-1R inhibitor (IC50: 1 nM), >1000-fold selective against its closest receptor tyrosine kinase homologs.
- $31
Size
QTY
CitedPazopanib Hydrochloride
Votrient HCl, Pazopanib HCl, GW786034 HCl, GW786034, Armala
T6930635702-64-6
Pazopanib Hydrochloride (Votrient HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
- $30
Size
QTY
Masitinib
AB1010
T2609790299-79-5
Masitinib (AB1010) is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.
- $31
Size
QTY
GW2580
GW 2580, SC-203877
T2659870483-87-7
GW2580 (SC-203877) is a specific, oral-bioavailable CSF-1R inhibitor for c-FMS.
- $43
Size
QTY
Linifanib
ABT-869, RG3635, AL-39324
T2514796967-16-3
Linifanib (AL-39324) (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR (IC50: 4 nM), CSF-1R (IC50: 3 nM), Flt-1/3 (IC50: 3/4 nM) and PDGFRβ (IC50: 66 nM). Linifanib may exhibit potent antiproliferative and apoptotic effects on tumor cells whose proliferation is dependent on mutant kinases, such as FMS-related tyrosine kinase receptor-3 (FLT3).
- $43
Size
QTY
Cerdulatinib hydrochloride
Cerdulatinib, PRT2070, PRT062070 hydrochloride, PRT062070, PRT2070 hydrochloride
T61041369761-01-2
Cerdulatinib hydrochloride (PRT2070 hydrochloride) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM.
- $37
Size
QTY
c-Fms-IN-13
T61589885704-58-5In house
c-Fms-IN-13 (compound 14) is a potent FMS kinase inhibitor (IC50 = 17 nM) and serves as an anti-inflammatory agent.
- $39
Size
QTY
c-Fms-IN-3
T10649885704-21-2In house
c-Fms-IN-3 is a novel inhibitor of c-FMS, suitable for research on antirheumatic and anti-inflammatory diseases.
- $46
Size
QTY
c-Fms-IN-1
T10643885703-64-0In house
c-Fms-IN-1 is an inhibitor of c-FMS kinase (IC50 = 0.8 nM).
- $35
Size
QTY
Onatasertib
CC223, CC 223, CC-223
T33511228013-30-6
Onatasertib (CC223) is an orally available mTOR inhibitor with potential antitumor activity. Onatasertib inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. Onatasertib is a potent mTOR kinase inhibitor (IC50: 16 nM), with >150-fold sensitivity than the related lipid kinase PI3Kα (IC50: 4 μM).
- $35
Size
QTY
Product Introduction
Bioactivity
Chemical Properties
| Description | cFMS Receptor Inhibitor II is a CSF1R kinase (FMS Receptor; colony stimulating factor 1 receptor; Macrophage colony-stimulating factor receptor) inhibitor with an IC50 of 2.8 nM, demonstrating significant selectivity over other kinases. This compound also exhibits notable CSF1R inhibition with an IC50 of 1.4 μM in cellular assays. |
| Molecular Weight | 368.43 |
| Formula | C23H20N4O |
| Cas No. | 959860-85-6 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 83.33 mg/mL (226.18 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy cFMS Receptor Inhibitor II | purchase cFMS Receptor Inhibitor II | cFMS Receptor Inhibitor II cost | order cFMS Receptor Inhibitor II | cFMS Receptor Inhibitor II chemical structure | cFMS Receptor Inhibitor II formula | cFMS Receptor Inhibitor II molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.